Last reviewed · How we verify
NCT06100965: ROSETTE
Reduced-dose Alemtuzumab for Kidney Transplant Rejection
trial in Kidney Transplant Rejection in 25 participants. Currently enrolling.
1 July 2025
Quick facts
| Lead sponsor | Erasmus Medical Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 25 |
| Start date | 1 December 2023 |
| Primary completion | 1 July 2025 |
| Estimated completion | 1 July 2026 |
| Sites | 1 location across Netherlands |
Conditions studied
- Kidney Transplant Rejection — all drugs for Kidney Transplant Rejection →
Sponsor
Erasmus Medical Center
Who can join
18 and older, any sex, with Kidney Transplant Rejection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospective, follow-up study of kidney transplant recipients treated with alemtuzumab anti-rejection therapy for severe or glucocorticoid-resistant kidney transplant rejection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06100965
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kidney Transplant Rejection
Currently open trials in the same condition.
- NCT07412470 — A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantati · Phase 2, PHASE3 · recruiting
- NCT07053462 — CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk · Phase 1, PHASE2 · recruiting
- NCT06564649 — PROACT Pilot Trial · active not recruiting
- NCT07006532 — Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab · NA · recruiting
- NCT07275541 — Platelet Aggregation in the Diagnosis of Acute Graft Rejection · recruiting
Other Erasmus Medical Center trials
Trials by the same sponsor.
- NCT07406269 — Clinical Evaluation of AI Decision Support for Early Rehabilitation After Surgery · NA · not yet recruiting
- NCT07402109 — CBCT Guided Markerless SBRT for Renal Cell Cancer · NA · recruiting
- NCT07383194 — Prediction Models for LDLT Outcomes · not yet recruiting
- NCT07426575 — Evaluating the Usability of New Dialysis Bags · not yet recruiting
- NCT07329296 — The Regenerative Capacity of the Donor Liver After Living Donor Liver Transplantation: an Ambidirectional Cohort Study · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06100965 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Erasmus Medical Center
- Last refreshed: 21 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06100965.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing